Search results for "antibodies"
								 					Article
				
				Elucidating Biosimilars Characterization
								In addition, some proteins, for example, monoclonal antibodies, have half-lives of weeks. These proteins would, therefore, require sample collection for many weeks to accurately define the pharmacokin…								
								 					Article
				
				Best Practices for Selecting a Top-Quality Cell Line
								Before scaling up to bioreactors, the productivity level for monoclonal antibodies (mAbs) should be 2–7 g/L (fed-batch culture in shake flask) or greater, observes Selexis CEO Igor Fisch. Once scaled …								
								 					Article
				
				Improving Process-Scale Chromatography
								More than 40 years of improvement in Protein A chromatography has resulted in well-established, robust purification processes for monoclonal antibodies,” Ljungqvist concludes. 
	Specifically, multim…								
								 					Article
				
				Analysis of Glycosylation in Biosimilars
								The structures of protein drugs such as monoclonal antibodies are made more complex by post-translational modifications. The most notable of these is glycosylation, where carbohydrate residues are att…								
								 					Article
				
				Implications of Cell Culture Conditions on Protein Glycosylation
								Multi-chain proteins, such as IgG antibodies, additionally have a quaternary structure resulting from structural associations between the subunits. 
	The choice of host-cell line for recombinant pro…								
								 					Article
				
				Ligand-Binding Assays and the Determination of Biosimilarity
								For monoclonal antibodies (mAbs), which make up a large portion of the biosimilars currently under development, it is important to remember that the different ends of the molecule are involved in bind…								
								 					Article
				
				Trends in BioPharma Approvals in 2013
								Engineered antibodies 
	
	Genentech’s Gazyva represents another milestone in antibody approvals, being the first glycoengineered mAb to come on the market in the US. mAbs are glycoproteins, carrying a…								
								 					Article
				
				ADC Development Robust Despite Lackluster Performance
								The company has developed a pipeline of ADCs, as well as antibodies and human-derived proteins, that target the tumor-associated stroma. For its ADC development, the company is developing antibodies t…								
								 					Article
				
				Patenting Prospects for Cell-Based Therapies
								The history of biomedical advances over the past 50 years has focused predominantly of increasing complexity, from small-molecule therapeutics to antibodies, cytokines, blood-clotting factors, and pro…								
								 					Article
				
				Biopharma in 2015: A Year for Approvals and Innovations
								…dic Counter-Current Chromatography
	Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies
	Trends in Single-use Bioreactors
	Process economy and production capacity using sin…